Biomedical Engineering Reference
In-Depth Information
53. Frankel AE, Burbage C, Fu T, Tagge E, Chandler J,
Willingham MC. (1996) Ricin toxin contains at least three
galactose-binding sites located in B chain subdomains 1 alpha,
1 beta, and 2 gamma. Biochemistry 35, 14749-14756.
54. Steeves RM, Denton ME, Barnard FC, Henry A, Lambert JM.
(1999) Identification of three oligosaccharide binding sites in
ricin. Biochemistry 38, 11677-11685.
55. Llorente A, Rapak A, Schmid SL, van Deurs B, Sandvig K.
(1998) Expression of mutant dynamin inhibits toxicity and
transport of endocytosed ricin to the Golgi apparatus. J. Cell.
Biol. 140, 553-563.
56. Grimmer S, Iversen TG, van Deurs B, Sandvig K. (2000)
Endosome to Golgi transport of ricin is regulated by choles-
terol. Mol. Biol. Cell 11, 4205-4216.
57. Girod A, Storrie B, Simpson JC, Johannes L, Goud B, Roberts
LM, et al. (1999) Evidence for a COP-I-independent transport
route from the Golgi complex to the endoplasmic reticulum.
Nat. Cell Biol. 1, 423-430.
58. Sandvig K, van Deurs B. (1999) Endocytosis and intracellular
transport of ricin: recent discoveries. FEBS Lett. 452, 67-70.
59. Wesche J, Rapak A, Olsnes S. (1999) Dependence of ricin
toxicity on translocation of the toxin A-chain from the
endoplasmic reticulum to the cytosol. J. Biol. Chem. 274,
34443-34449.
60. Endo Y, Mitsui K, Motizuki M, Tsurugi K. (1987) The
mechanism of action of ricin and related toxic lectins on
eukaryotic ribosomes. The site and the characteristics of the
modification in 28 S ribosomal RNA caused by the toxins.
J. Biol. Chem. 262, 5908-5912.
61. Lambert JM, Goldmacher VS, Collinson AR, Nadler LM,
Blattler WA. (1991) An immunotoxin prepared with blocked
ricin: a natural plant toxin adapted for therapeutic use. Cancer
Res. 51, 6236-6242.
62. Blakey DC, Skilleter DN, Price RJ, Watson GJ, Hart LI,
Newell DR. (1988) Comparison of the pharmacokinetics and
hepatotoxic effects of saporin and ricin A-chain immunotox-
ins on murine liver parenchymal cells. Cancer Res. 48, 7072-
7078.
63. Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown
AN, Watson GJ. (1988) Improved antitumor effects
of immunotoxins prepared with deglycosylated ricin
A-chain and hindered disulfide linkages. Cancer Res.
48, 6396-6403.
64. Blakey DC, Thorpe PE. (1986) Effect of chemical deglyco-
sylation on the in vivo fate of ricin A-chain. Cancer Drug
Deliv. 3, 189-196.
65. O'Hare M, Roberts LM, Thorpe PE, Watson GJ, Prior B, Lord
JM. (1987) Expression of ricin A chain in Escherichia coli.
FEBS Lett. 216, 73-78.
66. Stirpe F, Bailey S, Miller SP, Bodley JW. (1988) Modification
of ribosomal RNA by ribosome-inactivating proteins from
plants. Nucleic Acids Res. 16, 1349-1357.
67. Pirie CM, Hackel BJ, Rosenblum MG, Wittrup KD. (2011)
Convergent potency of internalized gelonin immunotoxins
across varied cell lines, antigens, and targeting moieties.
J. Biol. Chem. 286, 4165-4172.
68. Baykal U, Tumer NE. (2007) The C-terminus of pokeweed
antiviral protein has distinct roles in transport to the cytosol,
ribosome depurination and cytotoxicity. Plant J. 49, 995-1007.
69. Thompson J, Stavrou S, Weetall M, Hexham JM, Digan ME,
Wang Z, et al. (2001) Improved binding of a bivalent single-
chain immunotoxin results in increased efficacy for in vivo T-
cell depletion. Protein Eng. 14, 1035-1041.
70. Kim GB, Wang Z, Liu YY, Stavrou S, Mathias A, Goodwin
KJ. (2007) A fold-back single-chain diabody format enhances
the bioactivity of an anti-monkey CD3 recombinant diphthe-
ria toxin-based immunotoxin. Protein Eng. Des. Sel. 20,
425-432.
71. Vallera DA, Chen H, Sicheneder AR, Panoskaltsis-Mortari A,
Taras EP. (2009) Genetic alteration of a bispecific ligand-
directed toxin targeting human CD19 and CD22 receptors
resulting in improved efficacy against systemic B cell malig-
nancy. Leuk. Res. 33, 1233-1242.
72. Oh S, Ohlfest JR, Todhunter DA, Vallera VD, Hall WA, Chen
H. (2009) Intracranial elimination of human glioblastoma
brain tumors in nude rats using the bispecific ligand-directed
toxin, DTEGF13 and convection enhanced delivery. J. Neuro-
oncol. 95, 331-342.
73. Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA.
(2007) Increasing anticarcinoma activity of an anti-erbB2
recombinant immunotoxin by the addition of an anti-EpCAM
sFv. Clin. Cancer Res. 13, 3058-3067.
74. Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia
SO, Vallera DA. (2004) A bispecific immunotoxin (DTAT13)
targeting human IL-13 receptor (IL-13R) and urokinase-type
plasminogen activator receptor (uPAR) in a mouse xenograft
model. Protein Eng. Des. Sel. 17, 157-164.
75. Vallera DA, Oh S, Chen H, Shu Y, Frankel AE. (2010)
Bioengineering a unique deimmunized bispecific targeted
toxin that simultaneously recognizes human CD22 and
CD19 receptors in a mouse model of B-cell metastases.
Mol. Cancer Ther. 9, 1872-1883.
76. van Oosterhout YV, van Emst JL, Bakker HH, Preijers FW,
Schattenberg AV, Ruiter DJ. (2001) Production of anti-CD3
and anti-CD7 ricin A-immunotoxins for a clinical pilot study.
Int. J. Pharm. 221, 175-186.
77. Kernan NA, Knowles RW, Burns MJ, Broxmeyer HE, Lu L,
Lee HM. (1984) Specific inhibition of in vitro lymphocyte
transformation by an anti-pan T cell (gp67) ricin A chain
immunotoxin. J. Immunol. 133, 137-146.
78. LeMaistre CF, Rosen S, Frankel A, Kornfeld S, Saria E,
Meneghetti C. (1991) Phase I trial of H65-RTA immunocon-
jugate in patients with cutaneous T-cell lymphoma. Blood 78,
1173-1182.
79. Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, et al.
(1991) Phase I immunotoxin trial in patients with B-cell
lymphoma. Cancer Res. 51, 4052-4058.
80. Ghetie V, Ghetie MA, Uhr JW, Vitetta ES. (1988) Large scale
preparation of immunotoxins constructed with the Fab' frag-
ment of IgG1 murine monoclonal antibodies and chemically
deglycosylated ricin A chain. J. Immunol. Methods 112,
267-277.
Search WWH ::
Custom Search